The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials
Open accessAbstract
Summary Background Use of cell-based medicinal products (CBMPs) represents a state-of-the-art approach for reducing general immunosuppression in organ transplantation. We tested multiple regulatory CBMPs in kidney transplant trials to establish the safety of regulatory CBMPs when combined with reduced immunosuppressive treatment. Methods The ONE Study consisted of seven investigator-led, single-arm trials done internationally at eight hospitals in France, Germany, Italy, the UK, and the USA (60 week follow-up). Included patients were living-donor kidney transplant recipients aged 18 years and older. The reference group trial (RGT) was a standard-of-care group given basiliximab, tapered steroids, mycophenolate mofetil, and tacrolimus. Six non-randomised phase 1/2A cell therapy group (CTG) trials were pooled and analysed, in which patients received one of six CBMPs containing regulatory T cells, dendritic cells, or macrophages; patient selection and immunosuppression mirrored the RGT, except basiliximab induction was substituted with CBMPs and mycophenolate mofetil tapering was allowed. None of the trials were randomised and none of the individuals involved were masked. The primary endpoint was biopsyconfirmed acute rejection (BCAR) within 60 weeks after transplantation; adverse event coding was centralised. The RTG and CTG trials are registered with ClinicalTrials.gov, NCT01656135, NCT02252055, NCT02085629, NCT02244801, NCT02371434, NCT02129881, and NCT02091232. Findings The seven trials took place between Dec 11, 2012, and Nov 14, 2018. Of 782 patients assessed for eligibility, 130 (17%) patients were enrolled and 104 were treated and included in the analysis. The 66 patients who were treated in the RGT were 73% male and had a median age of 47 years. The 38 patients who were treated across six CTG trials were 71% male and had a median age of 45 years. Standard-of-care immunosuppression in the recipients in the RGT resulted in a 12% BCAR rate (expected range 3·2-18·0). The overall BCAR rate for the six parallel CTG trials was 16%. 15 (40%) patients given CBMPs were successfully weaned from mycophenolate mofetil and maintained on tacrolimus monotherapy. Combined adverse event data and BCAR episodes from all six CTG trials revealed no safety concerns when compared with the RGT. Fewer episodes of infections were registered in CTG trials versus the RGT. Interpretation Regulatory cell therapy is achievable and safe in living-donor kidney transplant recipients, and is associated with fewer infectious complications, but similar rejection rates in the first year. Therefore, immune cell therapy is a potentially useful therapeutic approach in recipients of kidney transplant to minimise the burden of general immunosuppression. Funding The 7th EU Framework Programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,810
Self-citationInfection in Organ Transplantation
Fishman, J. A. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14208 · Cited by 809
A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology
Roufosse, C., Simmonds, N., Clahsen-van Groningen, M., Haas, M., Henriksen, K. J., Horsfield, C., Loupy, A., Mengel, M., Perkowska-Ptasińska, A., Rabant, M., et al. (2018) · Transplantation · doi:10.1097/tp.0000000000002366 · Cited by 751
Todo, S., Yamashita, K., Goto, R., Zaitsu, M., Nagatsu, A., Oura, T., Watanabe, M., Aoyagi, T., Suzuki, T., Shimamura, T., et al. (2016) · Hepatology · doi:10.1002/hep.28459 · Cited by 441
Putnam, A. L., Safinia, N., Medvec, A., Laszkowska, M., Wray, M., Mintz, M. A., Trotta, E., Szot, G. L., Liu, W., Lares, A., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12433 · Cited by 261
Self-citationMathew, J. M., H.-Voss, J., LeFever, A., Konieczna, I., Stratton, C., He, J., Huang, X., Gallon, L., Skaro, A., Ansari, M. J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-25574-7 · Cited by 225
Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants
Chandran, S., Tang, Q., Sarwal, M., Laszik, Z. G., Putnam, A. L., Lee, K., Leung, J., Nguyen, V., Sigdel, T., Tavares, E. C., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14415 · Cited by 219
Self-citationStreitz, M., Miloud, T., Kapinsky, M., Reed, M. R., Magari, R., Geissler, E. K., Hutchinson, J. A., Vogt, K., Schlickeiser, S., Kverneland, A. H., et al. (2013) · Transplantation Research · doi:10.1186/2047-1440-2-17 · Cited by 214
Self-citationStrategies for long-term preservation of kidney graft function
Wekerle, T., Segev, D., Lechler, R., & Oberbauer, R. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31283-7 · Cited by 176
Self-citationFraser, H., Safinia, N., Grageda, N., Thirkell, S., Lowe, K., Fry, L., Scottà, C., Hope, A. J., Fisher, C., Hilton, R. M., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.006 · Cited by 143
Self-citation
Cited by
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment
Schulte-Schrepping, J., Reusch, N., Paclik, D., Baßler, K., Schlickeiser, S., Zhang, B., Krämer, B., Krammer, T., Brumhard, S., Bonaguro, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.001 · Cited by 1,461
Self-citationLong-Term Survival after Kidney Transplantation
Hariharan, S., Israni, A. K., & Danovitch, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2014530 · Cited by 664
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
Tolerogenic Dendritic Cells in Autoimmunity and Inflammatory Diseases
Morante-Palacios, O., Fondelli, F., Ballestar, E., & Martínez-Cáceres, E. M. (2021) · Trends in Immunology · doi:10.1016/j.it.2020.11.001 · Cited by 263
Complement activation induces excessive T cell cytotoxicity in severe COVID-19
Georg, P., Astaburuaga-García, R., Bonaguro, L., Brumhard, S., Michalick, L., Lippert, L. J., Kostevc, T., Gäbel, C., Schneider, M., Streitz, M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.040 · Cited by 218
“Briefly, whole blood samples collected from healthy controls spanning an age range between 20 and 84 years with equal distribution of females andmales in each 10-year age bin were stained using the ONE Study antibody panels as previously described (Sawitzki et al., 2020; Streitz et al., 2013) and acquired on a 10-Colo…”
Self-citation
Metadata
- Authors
- Sawitzki, B., Harden, P. N., Reinke, P., Moreau, A., Hutchinson, J. A., Game, D. S., Tang, Q., Guinan, E. C., Battaglia, M., Burlingham, W. J., Roberts, I. S. D., Streitz, M., Josien, R., Böger, C. A., Scottà, C., Markmann, J. F., Hester, J. L., Juerchott, K., Braudeau, C., James, B., Contreras-Ruiz, L., van der Net, J. B., Bergler, T., Caldara, R., Petchey, W., Edinger, M., Dupas, N., Kapinsky, M., Mutzbauer, I., Otto, N. M., Öllinger, R., Hernandez-Fuentes, M. P., Issa, F., Ahrens, N., Meyenberg, C., Karitzky, S., Kunzendorf, U., Knechtle, S. J., Grinyó, J., Morris, P. J., Brent, L., Bushell, A., Turka, L. A., Bluestone, J. A., Lechler, R. I., Schlitt, H. J., Cuturi, M. C., Schlickeiser, S., Friend, P. J., Miloud, T., Scheffold, A., Secchi, A., Crisalli, K., Kang, S.-M., Hilton, R., Banas, B., Blancho, G., Volk, H.-D., Lombardi, G., Wood, K. J., & Geissler, E. K.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 395
- Issue
- 10237
- Pages
- 1627-1639
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3026232934
- Cited by
- 458
- References
- 31
- FWCI
- 54.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. https://app.cochat.ai/papers/10.1016/s0140-6736(20)30167-7
- The paper
- Sawitzki, B., Harden, P. N., Reinke, P., Moreau, A., Hutchinson, J. A., Game, D. S., Tang, Q., Guinan, E. C., Battaglia, M., Burlingham, W. J., Roberts, I. S. D., Streitz, M., Josien, R., Böger, C. A., Scottà, C., Markmann, J. F., Hester, J. L., Juerchott, K., Braudeau, C., . . . Geissler, E. K. (2020). Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. The Lancet. https://doi.org/10.1016/s0140-6736(20)30167-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.